Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Rifampicin in treating S aureus bacteraemia – Authors’ reply

As Siegbert Reig and colleagues state in their letter, the ARREST trial found that in adults with Staphylococcus aureus bacteraemia, 14 days of adjunctive rifampicin had no significant effect on the composite primary endpoint of death or microbiologically-confirmed failure or recurrence after 12 weeks.1 However, contrary to their subsequent statements, rifampicin had no effect on treatment failure, only on recurrence, and the significant association between rifampicin and antibiotic-modifying adverse events and drug interactions was in the intention-to-treat population, not in a subgroup.

email